Edwards has exercised its option to acquire Endotronix, enhancing its capabilities in the heart failure management space. Credit: Umaporn Kensila / Shutterstock.

Edwards Lifesciences has announced strategic acquisitions of JenaValve Technology and Endotronix to expand its structural heart portfolio.

These investments aim to address unmet patient needs and drive long-term growth within the structural heart sector.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The upfront purchase price for these investments totals nearly $1.2bn, with the finalisation of the deals contingent on regulatory approvals.

JenaValve Technology provides transcatheter treatment of aortic regurgitation (AR). The company’s Trilogy Heart Valve System is expected to receive approval from the US Food and Drug Administration in late 2025 to treat AR.

Edwards has also exercised its option to acquire Endotronix, enhancing its capabilities in the heart failure (HF) management space.

See Also:

This acquisition is expected to expand Edwards’s structural heart portfolio into a new therapeutic area for addressing the needs of HF patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Edwards CEO Bernard Zovighian said: “These acquisitions expand our opportunities to address the unmet needs of aortic regurgitation and heart failure patients around the world.

“We are pleased to enter these structural heart therapeutic areas with innovation, world-class science and clinical evidence to provide access to life-saving technologies for patients around the world.”

These strategic moves are anticipated to boost Edwards’ position as a leader in structural heart innovation.

Furthermore, the company expects minimal revenue contribution from the acquisitions of JenaValve and Endotronix in 2025.

Last week, Edwards said it was exercising its option to acquire Israeli company Innovalve Bio Medical to advance its early-stage transcatheter mitral valve replacement (TMVR) business.

In an official filing with the US Securities and Exchange Commission, Edwards said it expects to pay around $300m in cash at the closing of the acquisition.